CancerLinQ CEO Kevin Fitzpatrick to Step Down; ASCO Chief Medical Officer Dr. Richard L. Schilsky Will Serve as Interim CEO

Apr 05, 2018

Kevin Fitzpatrick will step down from his role as chief executive officer of CancerLinQ LLC, a wholly owned nonprofit subsidiarity of ASCO, on April 13 to pursue a new opportunity outside of ASCO. Richard L. Schilsky, MD, FACP, FASCO, FSCT, chief medical officer (CMO) of ASCO, will serve as interim CEO. CancerLinQ LLC will initiate a global search for a permanent CEO to oversee the continued expansion and implementation of CancerLinQ®, ASCO’s big data platform designed to improve the quality of care for people with cancer.

“Under Kevin’s leadership we’ve taken CancerLinQ from a bold and ambitious idea to a reality for physicians and researchers across the country who seek to learn from everyday patient care,” said Clifford A. Hudis, MD, FACP, FASCO, CEO of ASCO and chair of the CancerLinQ Board of Governors. “He played a crucial role in establishing CancerLinQ, overseeing its roll-out to physician practices and securing novel strategic collaborations with government, for-profit, and nonprofit entities.”

“I’m incredibly grateful to the ASCO Board for granting me the privilege of leading this remarkably talented and dedicated team,” said Mr. Fitzpatrick. “I’m also grateful to our many supporters from across the oncology community. CancerLinQ has been propelled by a unique coalition of health care systems, sister societies, corporate supporters, governmental agencies, and ASCO members whose tireless support has been critical to our success.”

“We are fortunate to have Dr. Schilsky, with his extensive experience with CancerLinQ and oncology data, and his relationships throughout the oncology community, to step in to sustain our momentum through the transition,” said Dr. Hudis.

Dr. Schilsky brings decades of leadership experience in cancer science and patient care to his role as interim CancerLinQ CEO. He is a past president of ASCO and has served as CMO since 2012. In addition to being closely involved with CancerLinQ since its inception, he leads ASCO’s Center for Research & Analytics (CENTRA), which makes various cancer data sets—including CancerLinQ Discovery™—available to the oncology community and provides consultation and support for research and analysis. Dr. Schilsky’s full biography is available on ASCO’s website. 

Today, more than 100 oncology practices representing more than 2,000 oncologists have signed on to join CancerLinQ. The CancerLinQ database contains more than 1 million cancer patient records, making it already one of the largest and most comprehensive data sets of its kind. Through CancerLinQ Discovery, CancerLinQ LLC is providing access to high-quality, de-identified data sets derived from the real-world patient data contributed by participating practices. CancerLinQ LLC has established collaborations with government, nonprofit, and industry partners to generate new insights, improve patient care, and ensure the long-term financial sustainability of CancerLinQ.

CancerLinQ is overseen by its active and independent nine-member Board of Governors. The Board’s volunteer members are leaders in cancer care and research, technology, genomics, finance, and business, and have all played active roles in the development and roll-out of CancerLinQ to date.

CancerLinQ and CancerLinQ Discovery are projects of CancerLinQ LLC. Find more information on how to participate or partner with CancerLinQ.

Back to Top